RSBG SE verkauft Masco Group an Ardian
- Pascal Philipp Buck
- 29. Juli 2024
- 3 Min. Lesezeit
Aktualisiert: 18. Aug. 2024
Ardian gibt den Erwerb einer Mehrheitsbeteiligung an der Masco Group ("Masco") bekannt, einem globalen Anbieter von technischen Lösungen für die Pharma- und Biotech-Industrie. Ardian hat den Anteil von der RSBG SE, der Holding-Tochter der RAG-Stiftung, erworben. Die Familie Borella und das derzeitige Managementteam der Masco-Gruppe werden gemeinsam mit Ardian reinvestieren, und Luca Borella wird das Unternehmen weiterhin als CEO leiten.
Masco wurde 1912 gegründet und hat seinen Hauptsitz in Mailand. Das Unternehmen bietet eine Reihe von maßgeschneiderten Produkten und Dienstleistungen für die Biopharma- und Biowissenschaftsindustrie. Dazu gehören Reinstwassersysteme, Anlagen für die Bioprozessindustrie, modulare, außerhalb des Standorts hergestellte Anlagenlösungen, Verfahrenstechnik, Labor-, Validierungs- und Automatisierungsdienste. Zu den Kunden von Masco zählen die weltweit größten Biopharmaunternehmen und CDMOs, die in mehr als 80 Ländern vertreten sind. Masco ist weltweit mit 7 Standorten in Europa, Nordamerika und Asien vertreten.
Ardian wird seine Branchenkenntnis in den Bereichen Pharmazie und Biowissenschaften nutzen, um Masco in der nächsten Wachstumsphase nachhaltig zu unterstützen, die internationale Expansion voranzutreiben und Akquisitionen abzuschließen, die sich auf die Stärkung der technologischen Fähigkeiten des Unternehmens konzentrieren und gleichzeitig die operative Exzellenz fördern.
Luca Borella, CEO der Masco Gruppe, erklärt:
"I want to extend my sincere thanks to RSBG for their partnership since 2017, which has been invaluable. My gratitude also goes to the Masco Group management team, along with our dedicated colleagues, whose relentless efforts and outstanding achievements have laid a solid foundation for our ongoing and future success. I am particularly proud to mention my father, Alberto Borella, for his dedication and contribution to this journey and his decision to reinvesting and partnering with Ardian, ensuring continued success and stability of our business. Looking ahead, I am thrilled about the strategic growth plan we have outlined with Ardian, and I am delighted to welcome Angelos Papadimitriou as Chairman of the Board and Claudio Colombi as Director. I am confident the contribution of Ardian team will enhance our technological capabilities and operational excellence, ensuring we continue to meet the evolving needs of our clients and the industry at large.”
Dr. Klaus Lesker, CEO der RSBG SE, sagt:
“We are extremely pleased that in Ardian we have found a great new partner for Masco Group. Together with Ardian, Masco’s seasoned and outstanding management team will continue the growth path we have embarked on together over the past seven years. We are convinced that the Masco Group is excellently prepared for further technological development and geographical expansion in the healthcare, biotech and life sciences industry.”
Dr. Jan Gudlick, COO der RSBG SE unterstreicht:
“Since we partnered with Luca Borella and his family in 2017, we have jointly pursued an accelerated buy-and-build strategy with Masco Group. With 4 landmark acquisitions in 5 years, we have successfully inorganically enriched the offerings portfolio and geographic presence of Masco Group. We are extremely proud that together with the management team we were able to expand Masco’s range of advanced machinery solutions also in the field of modular prefabricated facilities for the pharmaceutical and biotech industry. We are confident, that Ardian is an excellent new home for Masco and the ideal partner for further growth over the next years.”
Marco Bellino, Geschäftsführer & stellvertretender Leiter des Bereichs Buyout Italien, Ardian erklärt:
"We are extremely happy to partner up with Luca Borella and his family to lead the next phase of growth of Masco. Together with RSBG, Luca and the management have created a global player in advanced engineering solutions for the life sciences industry. We are convinced that Masco is ideally poised to benefit from long-term tailwinds in the biotech industry, due to its deep engineering and process knowledge. We look forward to accelerating the Company’s international development organically and through an ambitious M&A strategy. This transaction is testament to Ardian’s expertise in investing in the most attractive niches within healthcare and partnering with leading entrepreneurial families. I am personally very excited to welcome Angelos Papadimitriou and Claudio Colombi as Chairman and Director of Masco Group, respectively. Angelos and Claudio bring a wealth of knowledge in leading industrial multinationals and will work alongside Luca to further establish Masco as a global leader in its market.”
Christopher Sand, Geschäftsführer Buyout, Ardian, ergänzt:
"Masco is an outstanding organization, and we are incredibly proud to partner with Luca Borella and the Masco team. Masco plays a vital role in the life sciences industry, with its portfolio of products and services supporting the production of numerous ground-breaking therapies and medications. With Ardian’s global reach and expanding presence in North America, we intend to accelerate Masco’s growth while providing their customers with a wider range of innovative products and services. Our investment in Masco exemplifies Ardian’s ability to harness our industry expertise, global reach, and collaborative approach with families and entrepreneurs alike.”
---------
